KR20230035586A - 고셔병을 치료하기 위한 아리모클로몰 - Google Patents

고셔병을 치료하기 위한 아리모클로몰 Download PDF

Info

Publication number
KR20230035586A
KR20230035586A KR1020237002548A KR20237002548A KR20230035586A KR 20230035586 A KR20230035586 A KR 20230035586A KR 1020237002548 A KR1020237002548 A KR 1020237002548A KR 20237002548 A KR20237002548 A KR 20237002548A KR 20230035586 A KR20230035586 A KR 20230035586A
Authority
KR
South Korea
Prior art keywords
pharmaceutical ingredient
active pharmaceutical
day
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237002548A
Other languages
English (en)
Korean (ko)
Inventor
토마스 키르케고르 옌젠
앤더스 뫼르케베르그 힌즈비
캐서린 콜스터 포그-퇴네센
린다 잉게만
달리 크리스틴 이
Original Assignee
켐팜 덴마크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 켐팜 덴마크 에이/에스 filed Critical 켐팜 덴마크 에이/에스
Publication of KR20230035586A publication Critical patent/KR20230035586A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237002548A 2020-06-24 2021-06-24 고셔병을 치료하기 위한 아리모클로몰 Pending KR20230035586A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20182067.7 2020-06-24
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
KR20230035586A true KR20230035586A (ko) 2023-03-14

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002548A Pending KR20230035586A (ko) 2020-06-24 2021-06-24 고셔병을 치료하기 위한 아리모클로몰

Country Status (14)

Country Link
US (1) US20230226036A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171559B1 (cg-RX-API-DMAC7.html)
JP (3) JP2023531750A (cg-RX-API-DMAC7.html)
KR (1) KR20230035586A (cg-RX-API-DMAC7.html)
CN (1) CN116075305A (cg-RX-API-DMAC7.html)
AU (1) AU2021295437A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026396A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4171559T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056005T3 (cg-RX-API-DMAC7.html)
IL (1) IL299250A (cg-RX-API-DMAC7.html)
MX (1) MX2023000033A (cg-RX-API-DMAC7.html)
PT (1) PT4171559T (cg-RX-API-DMAC7.html)
WO (1) WO2021260120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
JP5616336B2 (ja) * 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
AU2010281403B2 (en) * 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
ES2831764T3 (es) * 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL299250A (en) 2023-02-01
AU2021295437A1 (en) 2023-02-02
EP4171559A1 (en) 2023-05-03
BR112022026396A2 (pt) 2023-03-14
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
JP7849574B2 (ja) 2026-04-21
JP2026042936A (ja) 2026-03-11
JP2023531750A (ja) 2023-07-25
EP4171559B1 (en) 2025-09-10
ES3056005T3 (en) 2026-02-17
CN116075305A (zh) 2023-05-05
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
US20230226036A1 (en) 2023-07-20
DK4171559T3 (da) 2025-12-15
JP2026104910A (ja) 2026-06-25

Similar Documents

Publication Publication Date Title
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
EP3856478A1 (en) Formulations for treatment of dry eye disease
JP7849574B2 (ja) ゴーシェ病を処置するためのアリモクロモル
JP2018538273A (ja) 虚血性脳卒中を処置するための組成物および方法
US10016409B2 (en) Method for improving interstitial flow
Wienholtz et al. Infusion of pituitary adenylate cyclase–activating polypeptide-38 in patients with rosacea induces flushing and facial edema that can be attenuated by sumatriptan
KR20190039227A (ko) 신경퇴행성 질병을 위한 치료제
KR20200121819A (ko) 하지 불안 증후군을 치료하기 위한 치료제
JP2016523262A (ja) 慢性外傷性脳障害ｉｉを予防及び／又は治療する方法
CN118284412A (zh) 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗
US20190247405A1 (en) Treatment of sma
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
HK40090895B (en) Arimoclomol for treating gaucher disease
HK40090895A (en) Arimoclomol for treating gaucher disease
EP4559463A1 (en) Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders
KR102580507B1 (ko) 척수성 근위축성 측색 경화증 또는 뒤센 근이영양증의 예방 및 치료용 조성물
CN115364101A (zh) 治疗糖尿病周围神经病变的方法和药物组合物
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
ES2703693T3 (es) Métodos de tratamiento del prurito no histamínico en mamíferos
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
WO2024246686A1 (en) Treatment for amyotrophic lateral sclerosis (als)
Agent Pr SUTENT®
WO2014088106A1 (ja) 線維筋痛症の予防または治療薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302